JP2002510633A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510633A5
JP2002510633A5 JP2000542009A JP2000542009A JP2002510633A5 JP 2002510633 A5 JP2002510633 A5 JP 2002510633A5 JP 2000542009 A JP2000542009 A JP 2000542009A JP 2000542009 A JP2000542009 A JP 2000542009A JP 2002510633 A5 JP2002510633 A5 JP 2002510633A5
Authority
JP
Japan
Prior art keywords
mammalian
compound
pharmaceutical composition
excipient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000542009A
Other languages
English (en)
Japanese (ja)
Other versions
JP4443043B2 (ja
JP2002510633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/007471 external-priority patent/WO1999051238A1/en
Publication of JP2002510633A publication Critical patent/JP2002510633A/ja
Publication of JP2002510633A5 publication Critical patent/JP2002510633A5/ja
Application granted granted Critical
Publication of JP4443043B2 publication Critical patent/JP4443043B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000542009A 1998-04-06 1999-04-05 半合成エクテイナシジン Expired - Fee Related JP4443043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8080298P 1998-04-06 1998-04-06
US60/080,802 1998-04-06
PCT/US1999/007471 WO1999051238A1 (en) 1998-04-06 1999-04-05 Semi-synthetic ecteinascidins

Publications (3)

Publication Number Publication Date
JP2002510633A JP2002510633A (ja) 2002-04-09
JP2002510633A5 true JP2002510633A5 (enExample) 2006-05-25
JP4443043B2 JP4443043B2 (ja) 2010-03-31

Family

ID=22159716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542009A Expired - Fee Related JP4443043B2 (ja) 1998-04-06 1999-04-05 半合成エクテイナシジン

Country Status (27)

Country Link
US (1) US6124293A (enExample)
EP (2) EP1067933B1 (enExample)
JP (1) JP4443043B2 (enExample)
KR (1) KR100603219B1 (enExample)
CN (1) CN1157189C (enExample)
AT (1) ATE370148T1 (enExample)
AU (1) AU758100B2 (enExample)
BG (1) BG65088B1 (enExample)
BR (1) BR9909488B1 (enExample)
CA (1) CA2327468C (enExample)
CY (1) CY1106988T1 (enExample)
CZ (1) CZ301083B6 (enExample)
DE (1) DE69936845T2 (enExample)
DK (1) DK1067933T3 (enExample)
ES (1) ES2292237T3 (enExample)
HU (1) HUP0104273A3 (enExample)
IL (2) IL138856A0 (enExample)
MX (1) MXPA00009840A (enExample)
NO (1) NO328147B1 (enExample)
NZ (1) NZ507350A (enExample)
PL (1) PL196809B1 (enExample)
PT (1) PT1067933E (enExample)
RU (1) RU2217432C2 (enExample)
SK (1) SK285669B6 (enExample)
TR (1) TR200002921T2 (enExample)
UA (1) UA59439C2 (enExample)
WO (1) WO1999051238A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004529074A (ja) 2000-11-03 2004-09-24 プレジデント アンド フェロウズ オブ ハーバード カレッジ サフラマイシン、そのアナログ、およびその使用
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN100355775C (zh) * 2006-01-20 2007-12-19 南方医科大学 一种海鞘多肽及其制备方法
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
RU2738741C2 (ru) * 2016-02-04 2020-12-16 Цзянсу Хэнжуй Медицин Ко., Лтд. Инъекционная фармацевтическая композиция, включающая трабектедин, для применения вне желудочно-кишечного тракта и способ её получения
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
US5440055A (en) * 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Similar Documents

Publication Publication Date Title
WO2002020466B1 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY118156A (en) Oral compositions of levosimendan.
MXPA04003532A (es) Pirimidinonas como receptor 1 de la hormona concentradora de melanina.
CA2284732A1 (en) Analogs of cocaine
EP1422217A3 (en) Aminocyclohexyl ether compounds and uses thereof
AU7031500A (en) Therapeutic quinazoline compounds
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EP0709376A3 (en) Therapeutic compounds
EP1024145A3 (en) Novel azalides and methods of making same
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP1772142A3 (en) Organic compounds
CA2385890A1 (en) Controlled release compositions comprising nimesulide
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
JP2003522198A5 (enExample)
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
AU3850600A (en) Dalda analogs and their use
JP2002522501A5 (enExample)
EP0992509A3 (en) Novel macrolide derivatives
JP2002506864A5 (enExample)
PL342614A1 (en) Anticarcinogenic drugs
EP1431286A3 (en) Prodigiosin derivatives for treating cancer or viral diseases
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat